Trikalinos NA, et al. - Researchers compared disease control rate (DCR), disease progression, overall survival, and progression-free survival between patients with combined hepatocellular-cholangiocarcinoma tumors (cHCC-CCA) treated with different treatment modalities at a tertiary center. Histology, interventions, and outcomes of these patients were retrospectively examined. For patients in need of systemic treatment, gemcitabine/platinum seemed to be a better regimen. Compared to gemcitabine/platinum group, gemcitabine/5-fluoropyrimidine (5-FU) group experienced more disease progression, while DCR was better with gemcitabine/platinum. The gemcitabine/platinum group had better median PFS from time of initial diagnosis, however, the difference was not statistically significant.